
Opinion|Videos|July 12, 2024
MajesTEC-1 and the Value of Long-Term Follow-Up Data from ASCO 2024
Dr Garfall, MD, provides further insights around the MajesTEC-1 study.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Please provide your key takeaways from this study. How do these updated results impact the potential use of teclistamab in the management of RRMM?
- What is the value of long-term follow-up data in multiple myeloma? How does this impact treatment regimens?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Pembrolizumab Plus Enfortumab Vedotin for MIBC
2
Different Communication of HIV Risk Affects PrEP Interest
3
Global CKD Burden Nearly Doubles Since 1990, Reaching 788 Million Adults Worldwide
4
Pediatric AD Data Show Strong Safety and Efficacy for Tapinarof Cream: Druhan Howell, MD
5













































